• Publications
  • Influence
In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
Six opiate agonists were characterized by in vivo apparent pA2 analysis with respect to their discriminative stimulus, rate-decreasing and analgesic effects, by using the antagonist naltrexone. InExpand
  • 85
  • 8
Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency.
The antinociceptive effects of the opioid agonists etonitazene and alfentanil, as well as the agonist/antagonists nalbuphine, [(1)-beta-2'-hydroxy-2,9-dimethyl-5-phenyl-6,7-benzomorphan (GPA 1657)]Expand
  • 78
  • 8
Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure.
The apparent in vivo dissociation constant (KA) and relative efficacy values for alfentanil, etonitazene, morphine, and nalbuphine were determined by comparing the effects of these agonists in theExpand
  • 74
  • 6
Cannabidiol inhibits paclitaxel‐induced neuropathic pain through 5‐HT1A receptors without diminishing nervous system function or chemotherapy efficacy
Paclitaxel (PAC) is associated with chemotherapy‐induced neuropathic pain (CIPN) that can lead to the cessation of treatment in cancer patients even in the absence of alternate therapies. WeExpand
  • 107
  • 6
  • PDF
Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory
RationaleThe concern that adjuvant cancer chemotherapy agents cause cognitive impairment in a significant number of patients has been expressed by patients and healthcare providers, but clinicalExpand
  • 69
  • 5
Single and combined effects of Δ9‐tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy‐induced neuropathic pain
The non‐psychoactive phytocannabinoid cannabidiol (CBD) can affect the pharmacological effects of Δ9‐tetrahydrocannabinol (THC). We tested the possible synergy between CBD and THC in decreasingExpand
  • 54
  • 4
Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence
1 The purpose of the present study is to compare the capacity of opioid antagonists to elicit withdrawal jumping in mice following two acute pretreatment doses of the opioid agonist morphine.Expand
  • 21
  • 4
Potency Differences ford-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2as an Antagonist of Peptide and Alkaloid μ-Agonists in an Antinociception Assay
d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) is a peptide antagonist that demonstrates potent and selective affinity for μ-opioid receptors in radioligand binding assays and in vitro bioassays.Expand
  • 17
  • 4
Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers
RationaleAlthough buprenorphine is effective in treating opioid dependence, optimal maintenance doses of buprenorphine or the buprenorphine/naloxone combination have not yet beenExpand
  • 69
  • 3
  • PDF
Differential tolerance to antinociceptive effects of µ opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats
Abstract. Rationale: Repeated treatment experiments with high and low efficacy agonists provide critical insight into possible mechanisms underlying development of opioid tolerance. Objective:Expand
  • 67
  • 3